Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canakinumab + methotrexate
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral, Intramuscular
01
Overview
Canakinumab + methotrexate is a combination therapy involving canakinumab, a fully human monoclonal antibody targeting interleukin-1 beta (IL-1β), and methotrexate, a folate antimetabolite and immunosuppressant. Canakinumab neutralizes IL-1β, thereby reducing inflammation in autoinflammatory and autoimmune diseases. Methotrexate inhibits enzymes involved in nucleotide synthesis, leading to anti-inflammatory effects through increased extracellular adenosine. This combination has been studied primarily for the treatment of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate alone. Clinical trials have shown that adding canakinumab to stable doses of methotrexate improves therapeutic responses in active RA without significant new safety concerns[3][1]. The combination may also be used off-label or investigated for other inflammatory conditions.
- Other names
- ACZ885 + methotrexatecanakinumab + MTX
02
Targets
PPAT (Amidophosphoribosyltransferase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)IL1B (Interleukin-1 beta)TS (Thymidylate synthase)
Beyond the preview
Go deeper on canakinumab + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canakinumab + methotrexate.